Humane Genomics
A platform to make artificial viruses as cancer therapeutics.
Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading experts. We have in vivo (mouse) data showing safety and currently developing efficacy data and are showing 50% reduction in tumor volume.
Latest News
Active Founders
Peter Weijmarshausen, Founder
Building a highly efficient platform to make artificial viruses as cancer therapeutics.
Serial entrepreneur. Founder and former CEO of Shapeways.
Have built and led software and product teams for 3 companies.
Love to code, grow plants, brew beer, cook Asian food, and more.
BSc Applied Physics.
Chad Moles, Founder
Building a platform to engineer viruses as precision cancer therapies. Previous: Biotech, Columbia & Public Health, Tulane. Interested in sailing and pickleball.
